HealthEquity (NASDAQ:HQY) Reaches New 1-Year High – Still a Buy?

HealthEquity, Inc. (NASDAQ:HQY)’s share price hit a new 52-week high on Monday . The stock traded as high as $105.82 and last traded at $104.41, with a volume of 109861 shares. The stock had previously closed at $104.25.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. The Goldman Sachs Group started coverage on HealthEquity in a research report on Friday, November 15th. They set a “neutral” rating and a $108.00 price objective on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $92.00 price target on shares of HealthEquity in a report on Wednesday, September 4th. Bank of America upped their price objective on shares of HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. JMP Securities reaffirmed a “market outperform” rating and set a $105.00 target price on shares of HealthEquity in a research note on Wednesday, September 4th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on shares of HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.23.

HealthEquity Trading Down 1.1 %

The stock has a market cap of $8.95 billion, a price-to-earnings ratio of 86.18, a PEG ratio of 1.62 and a beta of 0.52. The company’s fifty day moving average is $88.75 and its two-hundred day moving average is $82.32. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.16. The company had revenue of $299.93 million for the quarter, compared to analysts’ expectations of $284.48 million. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. On average, research analysts predict that HealthEquity, Inc. will post 2.27 EPS for the current fiscal year.

Insider Activity at HealthEquity

In other news, Director Frank Corvino sold 1,247 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total value of $100,084.22. Following the completion of the sale, the director now directly owns 4,823 shares of the company’s stock, valued at approximately $387,093.98. The trade was a 20.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert W. Selander sold 8,250 shares of the firm’s stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total value of $684,585.00. Following the transaction, the director now owns 54,719 shares in the company, valued at $4,540,582.62. This represents a 13.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,536 shares of company stock valued at $884,517 over the last three months. 2.20% of the stock is owned by corporate insiders.

Institutional Trading of HealthEquity

Institutional investors and hedge funds have recently bought and sold shares of the business. GSA Capital Partners LLP purchased a new stake in shares of HealthEquity in the third quarter valued at about $638,000. Vaughan Nelson Investment Management L.P. raised its stake in HealthEquity by 36.7% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock valued at $69,034,000 after acquiring an additional 226,563 shares during the last quarter. Natixis Advisors LLC lifted its position in HealthEquity by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 209,175 shares of the company’s stock worth $17,122,000 after acquiring an additional 48,009 shares during the period. Oppenheimer Asset Management Inc. grew its stake in shares of HealthEquity by 29.4% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 64,214 shares of the company’s stock valued at $5,535,000 after purchasing an additional 14,573 shares during the last quarter. Finally, Diversify Wealth Management LLC acquired a new position in shares of HealthEquity in the second quarter valued at approximately $8,182,000. Hedge funds and other institutional investors own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.